Business
Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update
Not even the release of a positive announcement has been able to stop the Recce Pharmaceuticals Ltd (ASX: RCE) share price from dropping today.
In afternoon trade, the biotechnology company’s shares are down 2.5% to 94 cents.
What did Recce announce?
This afternoon Recce Pharmaceuticals announced that the European Patent Office has granted patents relating to Recce 327 (R327) and Recce 529 (R529).
R327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria. This includes their superbug forms.
Whereas R529 is a new synthetic polymer formulation with indication against viruses. Recce is currently undertaking initial studies of R529 to indicate any potential therapeutic effect…
-
General17 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News23 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General19 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business21 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years